These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


104 related items for PubMed ID: 1719285

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antihypertensive effects of cicletanine and renal protection in Dahl salt-sensitive rats.
    Uehara Y, Numabe A, Hirawa N, Kawabata Y, Iwai J, Ono H, Matsuoka H, Takabatake Y, Yagi S, Sugimoto T.
    J Hypertens; 1991 Aug; 9(8):719-28. PubMed ID: 1655882
    [Abstract] [Full Text] [Related]

  • 3. Restoration of endothelial cell function by chronic cicletanine treatment in Dahl salt-sensitive rats with salt-induced hypertension.
    Hirawa N, Uehara Y, Kawabata Y, Akie Y, Ichikawa A, Funahashi N, Goto A, Omata M.
    Hypertens Res; 1996 Dec; 19(4):263-70. PubMed ID: 8986457
    [Abstract] [Full Text] [Related]

  • 4. Lipid metabolism and renal protection by chronic cicletanine treatment in Dahl salt-sensitive rats with salt-induced hypertension.
    Uehara Y, Hirawa N, Kawabata Y, Akie Y, Ichikawa A, Funahashi N, Goto A, Omata M.
    Blood Press; 1997 May; 6(3):180-7. PubMed ID: 9181257
    [Abstract] [Full Text] [Related]

  • 5. The antihypertensive agent cicletanine reverses vascular hyperreactivity to noradrenaline and cardiac hypertrophy in DOCA-salt rats.
    Castro A, Parra L, Alsasua A, Fuentes JA.
    Arch Int Pharmacodyn Ther; 1990 May; 307():109-18. PubMed ID: 2151359
    [Abstract] [Full Text] [Related]

  • 6. Vascular actions of cicletanine.
    Bukoski RD, Wagman DW, de Wan P, Xue H.
    Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():45-50. PubMed ID: 2514668
    [Abstract] [Full Text] [Related]

  • 7. Possible radical scavenging properties of cicletanine and renal protection in Dahl salt sensitive rats.
    Uehara Y, Kawabata Y, Hirawa N, Takada S, Nagata T, Numabe A, Iwai J, Sugimoto T.
    Am J Hypertens; 1993 Jun; 6(6 Pt 1):463-72. PubMed ID: 8343228
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.
    Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY.
    Hypertension; 2003 Mar; 41(3):505-11. PubMed ID: 12623951
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nitric oxide, peroxynitrite and cGMP in atherosclerosis-induced hypertension in rabbits: beneficial effects of cicletanine.
    Szilvássy Z, Csont T, Páli T, Droy-Lefaix MT, Ferdinandy P.
    J Vasc Res; 2001 Mar; 38(1):39-46. PubMed ID: 11173993
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effect of cicletanine on vascular smooth muscle cell proliferation.
    Sato M, Abe K, Yasujima M, Omata K, Fang S, Tsunoda K, Kudo K, Takeuchi K, Hagino T, Kanazawa M.
    Arch Mal Coeur Vaiss; 1989 Nov; 82 Spec No 4():63-6. PubMed ID: 2514671
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Modifications of the arterial mechanical properties of normotensive and hypertensive rats without arterial pressure changes.
    Levy BI, Curmi P, Poitevin P, Safar ME.
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):253-9. PubMed ID: 2476599
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.